Graves' disease
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
thyroid storm
high-dose antithyroid drugs, corticosteroids, beta-blockers, iodine solution with supportive care
Thyroid storm is rare but typically develops in untreated or partially treated patients with poor access to the healthcare system.[84]Sherman SI, Simonson L, Ladenson PW. Clinical and socioeconomic predispositions to complicated thyrotoxicosis: a predictable and preventable syndrome? Am J Med. 1996 Aug;101(2):192-8. http://www.ncbi.nlm.nih.gov/pubmed/8757360?tool=bestpractice.com It can occur at any time, depending on precipitating factors. Rarely, thyroid storm may be the initial presentation.
Thyroid storm most commonly occurs postoperatively in a patient who is not medically prepared for surgery (i.e., the patient has not achieved peri-operative euthyroidism), or subsequent to the release of thyroid hormone following radioactive iodine therapy.[85]Palace MR. Perioperative management of thyroid dysfunction. Health Serv Insights. 2017;10:1178632916689677. https://journals.sagepub.com/doi/full/10.1177/1178632916689677 http://www.ncbi.nlm.nih.gov/pubmed/28469454?tool=bestpractice.com [86]Vennard K, Gilbert MP. Thyroid storm and complete heart block after treatment with radioactive iodine. Case Rep Endocrinol. 2018;2018:8214169. https://journals.sagepub.com/doi/10.1177/1178632916689677 http://www.ncbi.nlm.nih.gov/pubmed/29992062?tool=bestpractice.com Prevention with antithyroid drugs is important.
Thyroid storm presents with volume depletion, congestive heart failure, confusion, nausea and vomiting, and extreme agitation. Management includes supportive treatment such as cooling, correction of volume status, respiratory support if indicated, and treatment of underlying sepsis if appropriate. Thyroid storm should be managed in an intensive care environment with input from endocrine consultants.
High doses of antithyroid medications, corticosteroids, beta-blockers, and iodine solution (e.g., Lugol solution, or saturated solution of potassium iodide [SSKI]) should also be administered.[87]Turner BC. Thyroid emergencies part 1: Thyroid storm. CPD J Acute Med. 2004;3:93-5.[88]Vijayakumar V, Nusynowitz ML, Ali S. Is it safe to treat hyperthyroid patients with I-131 without fear of thyroid storm? Ann Nucl Med. 2006 Jul;20(6):383-5. http://www.ncbi.nlm.nih.gov/pubmed/16922465?tool=bestpractice.com Lugol solution must be given no earlier than 30 minutes after the first dose of antithyroid medication in order to avoid exacerbation of thyrotoxicosis due to escape from Wolff-Chaikoff effect. An alternative to Lugol solution and SSKI is sodium iodide, which is given intravenously; however, this is not available in some countries.[89]Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive Care Med. 2015 Mar;30(3):131-40. http://www.ncbi.nlm.nih.gov/pubmed/23920160?tool=bestpractice.com
Primary options
propylthiouracil: adults: 500-1000 mg orally initially as a loading dose, followed by 250 mg orally every 4 hours; 400-600 mg rectally every 6 hours
or
carbimazole: adults: consult specialist for guidance on dose
or
thiamazole: adults: consult specialist for guidance on dose
-- AND --
hydrocortisone: adults: 300 mg intravenously initially as a loading dose, followed by 100 mg every 8 hours
-- AND --
propranolol: adults: 60-80 mg orally (immediate-release) every 4-6 hours
or
esmolol: adults: 50-100 micrograms/kg/minute intravenous infusion
-- AND --
iodine/potassium iodide: (Lugol solution: iodine 5%/potassium iodine 10%) adults: 5 drops (250 mg) orally every 6 hours; consult specialist for guidance on rectal dose
or
potassium iodide: adults: (SSKI 1 g/mL) 0.1 to 0.3 mL (3-5 drops) orally three times daily
colestyramine
Additional treatment recommended for SOME patients in selected patient group
Colestyramine, a bile acid-sequestering agent, may be given to patients with thyroid storm to reduce the enterohepatic circulation of thyroid hormones.
Primary options
colestyramine: adults: 1-4 g orally twice daily
lithium
Additional treatment recommended for SOME patients in selected patient group
Lithium may be given to patients with thyroid storm to reduce thyroid hormone secretion.
Primary options
lithium: adults: 300 mg orally (regular-release) every 8 hours
subclinical Graves' disease
individualised treatment
Treatment of subclinical disease is individualised. Subclinical hyperthyroidism is associated with increased risk of atrial fibrillation, and an increased risk of bone loss in postmenopausal women who are not receiving oestrogen.[90]Cooper DS. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2007 Jan;92(1):3-9. http://www.ncbi.nlm.nih.gov/pubmed/17209221?tool=bestpractice.com When thyroid-stimulating hormone (TSH) is persistently <0.1 mIU/L, US guidelines recommend treating subclinical hyperthyroidism in the following patient populations: all individuals aged ≥65 years; those with cardiac risk factors, heart disease, or osteoporosis; postmenopausal women who are not on oestrogens or bisphosphonates; individuals with hyperthyroid symptoms.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
Subclinical hyperthyroidism due to Graves’ disease has an unpredictable course. In one study (median follow-up 32 months), approximately one third of patients remained in a subclinical hyperthyroid state, one third progressed to overt hyperthyroidism, and one third had spontaneous remission (normalised thyroid function); older individuals and those with positive antithyroid peroxidase (TPO) antibodies were at higher risk of progression.[16]Zhyzhneuskaya S, Addison C, Tsatlidis V, et al. The natural history of subclinical hyperthyroidism in Graves' disease: the rule of thirds. Thyroid. 2016 Jun;26(6):765-9. http://www.ncbi.nlm.nih.gov/pubmed/27090092?tool=bestpractice.com
symptomatic non-pregnant, non-lactating adults
prolonged antithyroid drug therapy
Antithyroid drugs, radioactive iodine, and surgery are all effective and relatively safe options for treating Graves’ hyperthyroidism.[79]Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20 https://www.doi.org/10.1210/clinem/dgaa646 http://www.ncbi.nlm.nih.gov/pubmed/32929476?tool=bestpractice.com Antithyroid drugs are increasingly the predominant therapy in developed countries.[92]Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab. 2012 Dec;97(12):4549-58. https://academic.oup.com/jcem/article/97/12/4549/2536521 http://www.ncbi.nlm.nih.gov/pubmed/23043191?tool=bestpractice.com [93]Brito JP, Schilz S, Singh Ospina N, et al. Antithyroid drugs - the most common treatment for graves' disease in the United States: a nationwide population-based study. Thyroid. 2016 Aug;26(8):1144-5. http://www.ncbi.nlm.nih.gov/pubmed/27267495?tool=bestpractice.com [94]Bartalena L, Burch HB, Burman KD, et al. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf). 2016 Jan;84(1):115-20. http://www.ncbi.nlm.nih.gov/pubmed/25581877?tool=bestpractice.com
Discuss the possible benefits and risks of these treatment options and the likelihood of a good response with patients (and their parents and carers, as appropriate) and take their preferences and values into account in addition to their clinical characteristics.
Antithyroid drugs block thyroid hormone synthesis. The group includes carbimazole, thiamazole, and propylthiouracil. Propylthiouracil also inhibits peripheral conversion of T4 to T3. This may be of benefit in the first few weeks of therapy in severe hyperthyroidism ('storm'), but thiamazole is a more potent drug and results in a more rapid return of T3 into the normal range weeks earlier than propylthiouracil.
Antithyroid drugs are used for a prolonged period of time (typically 12-18 months, but occasionally longer) to control the hyperthyroidism with the hope that the underlying autoimmune process will go into remission.
[ ]
In people with Graves' hyperthyroidism, what are the benefits and harms of different antithyroid drug regimens?/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.51/fullShow me the answer
Unless hyperthyroidism is mild, antithyroid drugs are usually administered initially at higher doses and titrated to lower maintenance doses depending on the biochemical response. Alternatively, high-dose antithyroid drugs can be administered continuously and then levothyroxine given for replacement therapy when the patient becomes euthyroid, which is usually 4-8 weeks after commencing treatment (i.e., the 'block and replace' approach).[100]Razvi S, Vaidya B, Perros P, et al. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol. 2006 Jun;154(6):783-6. http://www.eje-online.org/content/154/6/783.long http://www.ncbi.nlm.nih.gov/pubmed/16728536?tool=bestpractice.com The 'block and replace' strategy has been used less commonly in the US compared with Europe. The American Thyroid Association states that this approach is not generally recommended because it results in a higher rate of antithyroid drug adverse effects.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
European regulatory agencies have issued drug safety alerts regarding the risk of acute pancreatitis and the increased risk of congenital malformations (when administered during pregnancy) with the use of carbimazole and thiamazole.[105]European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. Jan 2019 [internet publication]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf [106]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: risk of acute pancreatitis. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-risk-of-acute-pancreatitis [107]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-increased-risk-of-congenital-malformations-strengthened-advice-on-contraception Propylthiouracil is associated with hepatic toxicity. Thiamazole should be used initially in all patients except during the first trimester of pregnancy due to its increased association with birth defects.[48]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018 Jul 25;7(4):167-86. https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml http://www.ncbi.nlm.nih.gov/pubmed/30283735?tool=bestpractice.com [108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Adverse effects of antithyroid drugs include the following.
Skin rash: in 7% to 12% of patients; if mild, may improve with antihistamine treatment.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com [109]Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. http://www.ncbi.nlm.nih.gov/pubmed/22332800?tool=bestpractice.com
Agranulocytosis: a rare adverse effect seen in 0.1% to 0.5% of patients.[110]Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83. http://www.ncbi.nlm.nih.gov/pubmed/24057289?tool=bestpractice.com All patients taking antithyroid drugs should be educated and warned about the early symptoms of agranulocytosis, and advised to stop taking the medicine and seek urgent medical attention if these symptoms develop.[111]Robinson J, Richardson M, Hickey J, et al. Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J. 2014 Dec;3(4):245-51. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311297 http://www.ncbi.nlm.nih.gov/pubmed/25759801?tool=bestpractice.com
Antineutrophil cytoplasmic antibody (ANCA)-positive small vessel vasculitis: symptoms manifest in approximately 3% of patients treated with antithyroid drugs; the risk is higher with propylthiouracil, younger patients, and increasing duration of treatment.[112]Balavoine AS, Glinoer D, Dubucquoi S, et al. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid. 2015 Dec;25(12):1273-81. http://www.ncbi.nlm.nih.gov/pubmed/26414658?tool=bestpractice.com
Relapse rate after a full course of therapy is reported to vary between 50% and 70% of patients but it may be lower in iodine-deficient areas.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com [102]Azizi F. The safety and efficacy of antithyroid drugs. Expert Opin Drug Saf. 2006 Jan;5(1):107-16. http://www.ncbi.nlm.nih.gov/pubmed/16370960?tool=bestpractice.com If antithyroid drugs are discontinued because of adverse effects or if relapse occurs after a course of therapy, treatment with radioactive iodine therapy or, in selected cases, surgical thyroidectomy may be considered.[108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds Some patients prefer a second course or longer term treatment with antithyroid drugs; there is some evidence that prolonged treatment may improve remission rates.[45]Chaker L, Cooper DS, Walsh JP, et al. Hyperthyroidism. Lancet. 2024 Feb 24;403(10428):768-80. http://www.ncbi.nlm.nih.gov/pubmed/38278171?tool=bestpractice.com [103]El Kawkgi OM, Ross DS, Stan MN. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature. Clin Endocrinol (Oxf). 2021 Jul;95(1):3-12. http://www.ncbi.nlm.nih.gov/pubmed/33283314?tool=bestpractice.com [104]Azizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial. Thyroid. 2019 Sep;29(9):1192-200. http://www.ncbi.nlm.nih.gov/pubmed/31310160?tool=bestpractice.com
Primary options
carbimazole: adults: 20-40 mg/day orally initially, adjust according to response; usual maintenance dose: 5-15 mg/day
OR
thiamazole: adults: consult specialist for guidance on dose
OR
Block and replace regimen
carbimazole: adults: 40-60 mg/day orally, titrate according to response
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
OR
Block and replace regimen
thiamazole: adults: consult specialist for guidance on dose
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
Secondary options
propylthiouracil: adults: 150-400 mg/day orally given in 3 divided doses initially, adjust according to response; usual maintenance dose: 50-150 mg/day
OR
Block and replace regimen
propylthiouracil: adults: 400 mg/day orally given in 3 divided doses initially, titrate according to response
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
symptomatic therapy
Additional treatment recommended for SOME patients in selected patient group
Offer a beta-blocker such as propranolol for early symptomatic relief until specific therapy normalises peripheral thyroid hormone levels. Beta-blockers ameliorate adrenergic symptoms such as tachycardia, tremor, and anxiety. Taper dose when specific therapy becomes effective. Beta-blockers are not indicated if there is a history of asthma, bradycardia, or heart block.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com Offer a calcium-channel blockers if beta-blockers are not tolerated or are contraindicated.
Primary options
propranolol: adults: 80-160 mg orally (extended-release) once daily
OR
atenolol: adults: 50-100 mg orally once daily
Secondary options
diltiazem: adults: 120-240 mg orally (extended-release) once daily
OR
verapamil: adults: 120-240 mg orally (extended-release) once daily
radioactive iodine for treatment failure
Additional treatment recommended for SOME patients in selected patient group
Radioactive iodine can be used as salvage therapy after failure of antithyroid drugs or surgery.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com
radioactive iodine ± corticosteroid
Antithyroid drugs, radioactive iodine, and surgery are all effective and relatively safe options for treating Graves’ hyperthyroidism.[79]Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20 https://www.doi.org/10.1210/clinem/dgaa646 http://www.ncbi.nlm.nih.gov/pubmed/32929476?tool=bestpractice.com
Discuss the possible benefits and risks of these treatment options and the likelihood of a good response with patients (and their parents and carers, as appropriate) and take their preferences and values into account in addition to their clinical characteristics.
Radioactive iodine is used both as first-line treatment and salvage therapy after failure of antithyroid drugs or surgery.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com
Treatment with radioactive iodine is associated with a reduced rate of recurrence of hyperthyroidism compared with treatment with antithyroid drugs.[96]Sjölin G, Holmberg M, Törring O, et al. The long-term outcome of treatment for Graves' hyperthyroidism. Thyroid. 2019 Nov;29(11):1545-57. http://www.ncbi.nlm.nih.gov/pubmed/31482765?tool=bestpractice.com [113]Ma C, Xie J, Wang H, et al. Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev. 2016 Feb 18;(2):CD010094. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010094.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/26891370?tool=bestpractice.com The intention of radioactive iodine therapy is to ablate the thyroid. The major sequela is permanent hypothyroidism requiring lifelong thyroxine replacement therapy.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com [91]Reinhardt MJ, Brink I, Joe AY, et al. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1118-24. http://www.ncbi.nlm.nih.gov/pubmed/12192554?tool=bestpractice.com [114]Haase A, Bahre M, Lauer I, et al. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000;108(2):133-7. http://www.ncbi.nlm.nih.gov/pubmed/10826521?tool=bestpractice.com
Transient hypothyroidism and recurrence of hyperthyroidism can occur in the initial months after therapy.[115]Stensvold AD, Jorde R, Sundsfjord J. Late and transient increases in free T4 after radioiodine treatment for Graves' disease. J Endocrinol Invest. 1997 Nov;20(10):580-4. http://www.ncbi.nlm.nih.gov/pubmed/9438914?tool=bestpractice.com [116]Chiovato L, Fiore E, Vitti P, et al. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998 Jan;83(1):40-6. http://www.ncbi.nlm.nih.gov/pubmed/9435414?tool=bestpractice.com [117]Perros P, Basu A, Boelaert K, et al. Postradioiodine Graves' management: the PRAGMA study. Clin Endocrinol (Oxf). 2022 Nov;97(5):664-5. http://www.ncbi.nlm.nih.gov/pubmed/35274331?tool=bestpractice.com Most patients will become hypothyroid following 6 months of radioactive iodine therapy if not replaced with levothyroxine. The aim should be to initiate levothyroxine before patients become clinically hypothyroid. Close monitoring is required.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com [117]Perros P, Basu A, Boelaert K, et al. Postradioiodine Graves' management: the PRAGMA study. Clin Endocrinol (Oxf). 2022 Nov;97(5):664-5. http://www.ncbi.nlm.nih.gov/pubmed/35274331?tool=bestpractice.com Hypothyroidism after radioactive iodine should be avoided as it constitutes a risk factor for the development or progression of orbitopathy.[118]Fatourechi V. Medical treatment of Graves' ophthalmopathy. Ophthalmol Clin North Am. 2000;13:683-91.[119]Tallstedt L, Lundell G, Blomgren H, et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994 May;130(5):494-7. http://www.ncbi.nlm.nih.gov/pubmed/8180678?tool=bestpractice.com
Attempts to partially ablate the thyroid and make the patient euthyroid are not successful and result in either late-onset hypothyroidism or relapse of hyperthyroidism. US guidelines recommend a single application of radioactive iodine sufficient to render patients with Graves' disease hypothyroid (10-15 millicuries [mCi] [370-555 megabecquerels {MBq}]). The fixed dose should be given after confirmation of adequate thyroid uptake.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
Radioactive iodine is contraindicated in pregnancy and during lactation.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com All women of childbearing age should have a pregnancy test prior to therapy.
Radioactive iodine is considered to be a poor choice for patients with active orbitopathy.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com Studies have found development or aggravation of orbitopathy in 15% to 38% of patients after radioactive iodine therapy.[113]Ma C, Xie J, Wang H, et al. Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev. 2016 Feb 18;(2):CD010094. http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD010094.pub2/full http://www.ncbi.nlm.nih.gov/pubmed/26891370?tool=bestpractice.com [120]Tallstedt L, Lundell G, Torring O, et al. Occurance of ophthalmopathy after treatment for Graves’ hyperthyroidism: the Thyroid Study Group. N Engl J Med. 1992 Jun 25;326(26):1733-8. http://www.nejm.org/doi/full/10.1056/NEJM199206253262603#t=article http://www.ncbi.nlm.nih.gov/pubmed/1489388?tool=bestpractice.com [121]Bartalena L, Tanda ML, Piantanida E, et al. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest. 2004 Mar;27(3):288-94. http://www.ncbi.nlm.nih.gov/pubmed/15165006?tool=bestpractice.com This may be prevented by concomitant corticosteroid therapy, especially for patients with pre-existing mild or moderate orbitopathy.[58]Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. https://www.doi.org/10.1530/EJE-21-0479 http://www.ncbi.nlm.nih.gov/pubmed/34297684?tool=bestpractice.com [121]Bartalena L, Tanda ML, Piantanida E, et al. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest. 2004 Mar;27(3):288-94. http://www.ncbi.nlm.nih.gov/pubmed/15165006?tool=bestpractice.com [122]Li HX, Xiang N, Hu WK, et al. Relation between therapy options for Graves' disease and the course of Graves' ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest. 2016 Nov;39(11):1225-33. http://www.ncbi.nlm.nih.gov/pubmed/27220843?tool=bestpractice.com Corticosteroids alongside radioactive iodine therapy can be given in patients with active orbitopathy in the absence of contraindications and when other treatment options for hyperthyroidism are inappropriate or have failed.[58]Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67. https://www.doi.org/10.1530/EJE-21-0479 http://www.ncbi.nlm.nih.gov/pubmed/34297684?tool=bestpractice.com [123]Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011 Mar;96(3):592-9. http://www.ncbi.nlm.nih.gov/pubmed/21190983?tool=bestpractice.com A short course of prednisolone tapered over 2-3 months is reasonable. Risks and benefits should be discussed with the patient.
An alternative approach is to wait until the orbitopathy is inactive before radioiodine treatment (without corticosteroids).
For patients with inactive or no evidence of orbitopathy, observation (without corticosteroids) is reasonable after radioactive iodine therapy without corticosteroids.
Radioactive iodine may present logistical barriers to its use due to the need for radiation precautions (e.g., for parents with young children, or older patients with incontinence [who may present unacceptable risk to their carer]).[125]Sisson JC, Freitas J, McDougall IR, et al; American Thyroid Association Taskforce on Radioiodine Safety. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid. 2011 Apr;21(4):335-46. https://www.liebertpub.com/doi/10.1089/thy.2010.0403 http://www.ncbi.nlm.nih.gov/pubmed/21417738?tool=bestpractice.com
Primary options
prednisolone: adults: 30-40 mg orally once daily for 4 weeks, then taper gradually over 2-3 months; lower doses may be as effective
antithyroid drug pre- and/or post-radioactive iodine
Additional treatment recommended for SOME patients in selected patient group
Antithyroid drugs can be used as adjunctive therapy to normalise thyroid function before radioactive iodine therapy.
Pre-treatment with an antithyroid drug may be considered for patients at increased risk of complications (e.g., older adults, very symptomatic patients, and those with comorbidities).[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
Taken until the patient is euthyroid (usually several weeks), antithyroid drugs should be stopped before radioactive iodine therapy (generally 3 days before) and then restarted 3-5 days after completion of radioactive iodine therapy. Antithyroid drugs are then tapered and stopped as the patient becomes euthyroid or hypothyroid after radioactive iodine therapy (usually 1-3 months).[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
European regulatory agencies have issued drug safety alerts regarding the risk of acute pancreatitis and the increased risk of congenital malformations (when administered during pregnancy) with the use of carbimazole and thiamazole.[105]European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. Jan 2019 [internet publication]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf [106]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: risk of acute pancreatitis. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-risk-of-acute-pancreatitis [107]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-increased-risk-of-congenital-malformations-strengthened-advice-on-contraception Propylthiouracil is associated with hepatic toxicity. Thiamazole should be used initially in all patients except during the first trimester of pregnancy due to its increased association with birth defects.[48]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018 Jul 25;7(4):167-86. https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml http://www.ncbi.nlm.nih.gov/pubmed/30283735?tool=bestpractice.com [108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Adverse effects of antithyroid drugs include the following.
Skin rash: develops in 7% to 12% of patients; if mild, may improve with antihistamine treatment.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com [109]Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. http://www.ncbi.nlm.nih.gov/pubmed/22332800?tool=bestpractice.com
Agranulocytosis: a rare adverse effect seen in 0.1% to 0.5% of patients.[110]Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83. http://www.ncbi.nlm.nih.gov/pubmed/24057289?tool=bestpractice.com All patients taking antithyroid drugs should be educated and warned about the early symptoms of agranulocytosis, and advised to stop taking the medicine and seek urgent medical attention if these symptoms develop.[111]Robinson J, Richardson M, Hickey J, et al. Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J. 2014 Dec;3(4):245-51. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311297 http://www.ncbi.nlm.nih.gov/pubmed/25759801?tool=bestpractice.com
Antineutrophil cytoplasmic antibody (ANCA)-positive small vessel vasculitis: symptoms manifest in approximately 3% of patients treated with antithyroid drugs; the risk is higher with propylthiouracil, younger patients, and increasing duration of treatment.[112]Balavoine AS, Glinoer D, Dubucquoi S, et al. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid. 2015 Dec;25(12):1273-81. http://www.ncbi.nlm.nih.gov/pubmed/26414658?tool=bestpractice.com
Unless hyperthyroidism is mild, antithyroid drugs are usually administered initially at higher doses and titrated to lower maintenance doses depending on the biochemical response. Alternatively, high-dose antithyroid drugs can be administered continuously and then levothyroxine given for replacement therapy when the patient becomes euthyroid, which is usually 4-8 weeks after commencing treatment (i.e., the 'block and replace' approach).[100]Razvi S, Vaidya B, Perros P, et al. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol. 2006 Jun;154(6):783-6. http://www.eje-online.org/content/154/6/783.long http://www.ncbi.nlm.nih.gov/pubmed/16728536?tool=bestpractice.com The 'block and replace' strategy has been used less commonly in the US compared with Europe. The American Thyroid Association states that this approach is not generally recommended because it results in a higher rate of antithyroid drug adverse effects.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
Primary options
carbimazole: adults: 20-40 mg/day orally initially, adjust according to response; usual maintenance dose: 5-15 mg/day
OR
thiamazole: adults: consult specialist for guidance on dose
OR
Block and replace regimen
carbimazole: adults: 40-60 mg/day orally, titrate according to response
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
OR
Block and replace regimen
thiamazole: adults: consult specialist for guidance on dose
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
Secondary options
propylthiouracil: adults: 150-400 mg/day orally given in 3 divided doses initially, adjust according to response; usual maintenance dose: 50-150 mg/day
OR
Block and replace regimen
propylthiouracil: adults: 400 mg/day orally given in 3 divided doses initially, titrate according to response
and
levothyroxine: adults: 100-150 micrograms/day orally when patient is euthyroid
symptomatic therapy
Additional treatment recommended for SOME patients in selected patient group
Offer a beta-blocker such as propranolol for early symptomatic relief until specific therapy normalises peripheral thyroid hormone levels.
Beta-blockers ameliorate adrenergic symptoms such as tachycardia, tremor, and anxiety.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com Taper dose when specific therapy becomes effective. Beta-blockers are not indicated if there is a history of asthma, bradycardia, or heart block.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com Calcium-channel blockers are an alternative if beta-blockers are not tolerated or are contraindicated.
Primary options
propranolol: adults: 80-160 mg orally (extended-release) once daily
OR
atenolol: adults: 50-100 mg orally once daily
Secondary options
diltiazem: adults: 120-240 mg orally (extended release) once daily
OR
verapamil: adults: 120-240 mg orally once daily
post-therapy thyroid hormone replacement
Additional treatment recommended for SOME patients in selected patient group
Most patients will become hypothyroid by 6 months after radioactive iodine therapy if not replaced with levothyroxine. The aim should be to initiate levothyroxine before patients become clinically hypothyroid. Close monitoring is required.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com [117]Perros P, Basu A, Boelaert K, et al. Postradioiodine Graves' management: the PRAGMA study. Clin Endocrinol (Oxf). 2022 Nov;97(5):664-5. http://www.ncbi.nlm.nih.gov/pubmed/35274331?tool=bestpractice.com Hypothyroidism after radioactive iodine should be avoided as it constitutes a risk factor for the development or progression of orbitopathy.[119]Tallstedt L, Lundell G, Blomgren H, et al. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994 May;130(5):494-7. http://www.ncbi.nlm.nih.gov/pubmed/8180678?tool=bestpractice.com
Replacement thyroxine therapy should initially be monitored with serum thyroid-stimulating hormone (TSH) and free T4 at 6-week intervals until stable, then with serum TSH at least annually. Measurement of free T4 is a much less sensitive parameter of the thyroid metabolic state. However, when pituitary TSH production is suppressed by a prolonged period of thyrotoxic state due to high TSH receptor antibodies, it may take some months for pituitary function to recover; during that interval, measurement of serum TSH may be misleading, and free T4 may give a better indication of thyroid status.
Primary options
levothyroxine: adults: 1.7 micrograms/kg/day orally, adjust dose according to response and laboratory values
thyroid surgery
Antithyroid drugs, radioactive iodine, and surgery are all effective and relatively safe options for treating Graves' hyperthyroidism.[79]Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20 https://www.doi.org/10.1210/clinem/dgaa646 http://www.ncbi.nlm.nih.gov/pubmed/32929476?tool=bestpractice.com
Discuss the possible benefits and risks of these treatment options and the likelihood of a good response with patients (and their parents and carers, as appropriate) and take their preferences and values into account in addition to their clinical characteristics.
Surgery may be preferred in the following scenarios:[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
women planning a pregnancy in <6 months provided thyroid hormone levels are normal;
symptomatic compression or large goitres;
relatively low uptake of radioactive iodine;
cases when thyroid malignancy is documented or suspected;
large thyroid nodules;
co-existing hyperparathyroidism requiring surgery; and
patients with moderate-to-severe active Graves' orbitopathy.
Surgery may be open or employ a minimally invasive approach. Total or near-total thyroidectomy is preferred over bilateral subtotal thyroidectomy as it prevents recurrent hyperthyroidism; if the patient is euthyroid at the time of surgery, levothyroxine is started immediately postoperatively.[127]Stålberg P, Svensson A, Hessman O, et al. Surgical treatment of Graves' disease: evidence-based approach. World J Surg. 2008 Jul;32(7):1269-77.
http://www.ncbi.nlm.nih.gov/pubmed/18327526?tool=bestpractice.com
[128]Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg. 2012 Apr;99(4):515-22.
http://www.ncbi.nlm.nih.gov/pubmed/22287122?tool=bestpractice.com
[ ]
How do different thyroid surgery techniques compare for people with Graves’ disease and Graves’ ophthalmopathy?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2252/fullShow me the answer[Evidence B]992f1865-0876-4ac5-99cf-722258c0137fccaBHow do different thyroid surgery techniques compare for people with Graves’ disease and Graves’ ophthalmopathy?
The incidence of hypoparathyroidism and vocal cord paralysis (recurrent laryngeal nerve damage) following surgery by experienced surgeons is approximately 2% and 1%, respectively.[129]Roher HD, Goretzki PE, Hellmann P, et al. Complications in thyroid surgery: incidence and therapy [in German]. Chirurg. 1999 Sep;70(9):999-1010. http://www.ncbi.nlm.nih.gov/pubmed/10501664?tool=bestpractice.com Whether intraoperative monitoring of the recurrent laryngeal nerve reduces complications is controversial.[130]Barczynski M, Konturek A, Stopa M, et al. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg. 2012 Jun;36(6):1340-7. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348444 http://www.ncbi.nlm.nih.gov/pubmed/22402975?tool=bestpractice.com [131]Cavicchi O, Caliceti U, Fernandez IJ, et al. Laryngeal neuromonitoring and neurostimulation versus neurostimulation alone in thyroid surgery: a randomized clinical trial. Head Neck. 2012 Feb;34(2):141-5. http://www.ncbi.nlm.nih.gov/pubmed/21469244?tool=bestpractice.com
Other surgical risks include bleeding, infection, and keloid formation. Endoscopic minimally invasive surgery appears to be associated with reduced rates of blood loss and better cosmetic results compared with open surgery, but with longer operation times.[132]Zhang Y, Dong Z, Li J, et al. Comparison of endoscopic and conventional open thyroidectomy for Graves' disease: a meta-analysis. Int J Surg. 2017 Apr;40:52-9.
http://www.ncbi.nlm.nih.gov/pubmed/28235670?tool=bestpractice.com
Rates of transient recurrent laryngeal nerve palsy, transient hypocalcaemia, postoperative hypothyroidism, and recurrent hyperthyroidism were equivalent between the minimally invasive and open groups.[132]Zhang Y, Dong Z, Li J, et al. Comparison of endoscopic and conventional open thyroidectomy for Graves' disease: a meta-analysis. Int J Surg. 2017 Apr;40:52-9.
http://www.ncbi.nlm.nih.gov/pubmed/28235670?tool=bestpractice.com
Several factors inform suitability for minimally invasive surgery, including total thyroid volume not exceeding 25 mL as measured by ultrasound.[133]Miccoli P, Fregoli L, Rossi L, et al. Minimally invasive video-assisted thyroidectomy (MIVAT). Gland Surg. 2020 Jan;9(suppl 1):S1-S5.
https://www.doi.org/10.21037/gs.2019.12.05
http://www.ncbi.nlm.nih.gov/pubmed/32055492?tool=bestpractice.com
Total or near-total thyroidectomy is preferred over bilateral subtotal thyroidectomy as it prevents recurrent hyperthyroidism; if the patient is euthyroid at the time of surgery, levothyroxine therapy is started immediately postoperatively.[128]Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg. 2012 Apr;99(4):515-22.
http://www.ncbi.nlm.nih.gov/pubmed/22287122?tool=bestpractice.com
[146]Thompson GB. Surgical management in Graves' disease. Panminerva Med. 2002 Dec;44(4):287-93.[147]Barakate MS, Agarwal G, Reeve TS, et al. Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg. 2002 May;72(5):321-4.
http://www.ncbi.nlm.nih.gov/pubmed/12028087?tool=bestpractice.com
[ ]
How do different thyroid surgery techniques compare for people with Graves’ disease and Graves’ ophthalmopathy?/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2252/fullShow me the answer[Evidence B]992f1865-0876-4ac5-99cf-722258c0137fccaBHow do different thyroid surgery techniques compare for people with Graves’ disease and Graves’ ophthalmopathy?
preoperative medical preparation
Treatment recommended for ALL patients in selected patient group
Antithyroid drugs can be used as adjunctive therapy to normalise thyroid function before surgery. Antithyroid drugs are stopped at the time of thyroidectomy.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com
Some clinics treat patients 7-10 days prior to surgery with pharmacological doses of iodine (e.g., Lugol solution or SSKI) to reduce vascularity of the thyroid gland, leading to less intraoperative blood loss.[126]Whalen G, Sullivan M, Maranda L, et al. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves' disease. Am J Surg. 2017 Apr;213(4):805-9. http://www.ncbi.nlm.nih.gov/pubmed/27769543?tool=bestpractice.com Iodine is contraindicated in pregnancy at all times as it may inhibit fetal thyroid function to an extent that goitre and even congenital hypothyroidism may ensue.
European regulatory agencies have issued drug safety alerts regarding the risk of acute pancreatitis and the increased risk of congenital malformations (when administered during pregnancy) with the use of carbimazole and thiamazole.[105]European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. Jan 2019 [internet publication]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf [106]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: risk of acute pancreatitis. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-risk-of-acute-pancreatitis [107]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-increased-risk-of-congenital-malformations-strengthened-advice-on-contraception Propylthiouracil is associated with hepatic toxicity. Thiamazole should be used initially in all patients except during the first trimester of pregnancy due to its increased association with birth defects.[48]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018 Jul 25;7(4):167-86. https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml http://www.ncbi.nlm.nih.gov/pubmed/30283735?tool=bestpractice.com [108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Adverse effects of antithyroid drugs include the following.
Skin rash: develops in 7% to 12% of patients; if mild, may improve with antihistamine treatment.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com [109]Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. http://www.ncbi.nlm.nih.gov/pubmed/22332800?tool=bestpractice.com
Agranulocytosis: a rare adverse effect seen in 0.1% to 0.5% of patients.[110]Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83. http://www.ncbi.nlm.nih.gov/pubmed/24057289?tool=bestpractice.com All patients taking antithyroid drugs should be educated and warned about the early symptoms of agranulocytosis, and advised to stop taking the medicine and seek urgent medical attention if these symptoms develop.[111]Robinson J, Richardson M, Hickey J, et al. Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J. 2014 Dec;3(4):245-51. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311297 http://www.ncbi.nlm.nih.gov/pubmed/25759801?tool=bestpractice.com
Antineutrophil cytoplasmic antibody (ANCA)-positive small vessel vasculitis: symptoms manifest in approximately 3% of patients treated with antithyroid drugs; the risk is higher with propylthiouracil, younger patients, and increasing duration of treatment.[112]Balavoine AS, Glinoer D, Dubucquoi S, et al. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid. 2015 Dec;25(12):1273-81. http://www.ncbi.nlm.nih.gov/pubmed/26414658?tool=bestpractice.com
Offer a beta-blocker such as propranolol for early symptomatic relief until surgery normalises peripheral thyroid hormone levels. Beta-blockers ameliorate adrenergic symptoms such as tachycardia, tremor, and anxiety.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com Taper dose following surgery. Beta-blockers are not indicated if there is a history of asthma, bradycardia, or heart block.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com Calcium-channel blockers are an alternative if beta-blockers are not tolerated or are contraindicated.
Primary options
propranolol: adults: 80-160 mg orally (extended-release) once daily
or
atenolol: adults: 50-100 mg orally once daily
-- AND / OR --
carbimazole: adults: 20-40 mg/day orally initially, adjust according to response; usual maintenance dose: 5-15 mg/day
or
thiamazole: adults: consult specialist for guidance on dose
or
propylthiouracil: adults: 150-400 mg/day orally given in 3 divided doses initially, adjust according to response; usual maintenance dose: 50-150 mg/day
-- AND / OR --
iodine/potassium iodide: (Lugol solution: iodine 5%/potassium iodine 10%) adults: 5 drops (250 mg) orally every 6 hours for 7-10 days before surgery
or
potassium iodide: adults: (SSKI 1 g/mL) 0.1 to 0.3 mL (3-5 drops) orally three times daily for 7-10 days before surgery
postoperative thyroid replacement
Treatment recommended for ALL patients in selected patient group
Treatment with levothyroxine is as indicated for hypothyroidism. Replacement thyroxine therapy should initially be monitored with serum thyroid-stimulating hormone (TSH) and free T4 at 6-week intervals until stable, then with serum TSH at least annually. Measurement of free T4 is a much less sensitive parameter of the thyroid metabolic state. However, when pituitary TSH production is suppressed by a prolonged period of thyrotoxic state due to high TSH receptor antibodies, it may take some months for pituitary function to recover; during that interval, measurement of serum TSH may be misleading, and free T4 may give a better indication of thyroid status.
Primary options
levothyroxine: adults: 1.7 micrograms/kg/day orally, adjust dose according to response and laboratory values
radioactive iodine for treatment failure
Additional treatment recommended for SOME patients in selected patient group
Radioactive iodine can be used as salvage therapy after failure of antithyroid drugs or surgery.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com
pregnant women
antithyroid drug
Antithyroid drugs are used to treat pregnant women; radioactive iodine is contraindicated in pregnancy.
Antithyroid drugs can cross the placenta and affect fetal thyroid function, so the lowest possible dose should be used.[105]European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. Jan 2019 [internet publication]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf The goal of treatment is a serum free T4 level at, or moderately above, the normal range for pregnancy.[76]Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar;27(3):315-89. https://www.liebertpub.com/doi/10.1089/thy.2016.0457 http://www.ncbi.nlm.nih.gov/pubmed/28056690?tool=bestpractice.com Therefore, many women with mild hyperthyroidism during pregnancy are closely monitored and not treated. However, data from a population-based prospective cohort study indicated a negative impact of mild maternal thyrotoxicosis on the IQ of the offspring.[134]Korevaar TI, Muetzel R, Medici M, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. Lancet Diabetes Endocrinol. 2016 Jan;4(1):35-43. http://www.ncbi.nlm.nih.gov/pubmed/26497402?tool=bestpractice.com
Women who are already on treatment with antithyroid drugs for managing Graves’ disease and who are contemplating pregnancy should be switched to propylthiouracil (if on carbimazole therapy). When pregnancy is confirmed and if the disease appears to be in remission (low or negative thyroid-stimulating hormone [TSH] receptor antibodies) antithyroid drugs can be withdrawn and thyroid functions repeated.[76]Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar;27(3):315-89. https://www.liebertpub.com/doi/10.1089/thy.2016.0457 http://www.ncbi.nlm.nih.gov/pubmed/28056690?tool=bestpractice.com
Propylthiouracil is preferred in the first trimester of pregnancy. While all antithyroid drugs have been associated with birth defects, those associated with thiamazole and carbimazole are more common and more severe than those associated with propylthiouracil.[135]Andersen SL, Olsen J, Wu CS, et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013 Nov;98(11):4373-81. http://www.ncbi.nlm.nih.gov/pubmed/24151287?tool=bestpractice.com [136]Andersen SL, Olsen J, Wu CS, et al. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014 Oct;24(10):1533-40. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195247 http://www.ncbi.nlm.nih.gov/pubmed/24963758?tool=bestpractice.com [137]Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021 Oct;87(10):3890-900. https://www.doi.org/10.1111/bcp.14805 http://www.ncbi.nlm.nih.gov/pubmed/33783857?tool=bestpractice.com
One systematic review and meta-analysis of observational studies reported the following absolute excess risks associated with antithyroid drug exposure (compared with an unexposed general population) for birth defects (any/major): propylthiouracil (10.2/1.3 per 1000 live births); thiamazole/carbimazole (17.8/2.3); untreated hyperthyroidism (9.6/1.2).[137]Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021 Oct;87(10):3890-900. https://www.doi.org/10.1111/bcp.14805 http://www.ncbi.nlm.nih.gov/pubmed/33783857?tool=bestpractice.com
US guidelines on the management of thyroid disease in pregnancy state that consideration can be given to discontinuing propylthiouracil after the first trimester and switching to thiamazole in order to decrease the risk of liver failure in the mother. However, due to insufficient evidence, it makes no recommendation.[76]Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar;27(3):315-89. https://www.liebertpub.com/doi/10.1089/thy.2016.0457 http://www.ncbi.nlm.nih.gov/pubmed/28056690?tool=bestpractice.com Treatment can continue for 12-18 months. Relapse rate after a full course of therapy is reported to vary between 50% and 70% of patients.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com It is possible to discontinue treatment with antithyroid drugs in 20% to 30% of women in the last trimester of pregnancy.[76]Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar;27(3):315-89. https://www.liebertpub.com/doi/10.1089/thy.2016.0457 http://www.ncbi.nlm.nih.gov/pubmed/28056690?tool=bestpractice.com
Antithyroid drugs at low to moderate doses are thought to be safe for infants of lactating women.[76]Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017 Mar;27(3):315-89. https://www.liebertpub.com/doi/10.1089/thy.2016.0457 http://www.ncbi.nlm.nih.gov/pubmed/28056690?tool=bestpractice.com
European regulatory agencies have issued drug safety alerts regarding the risk of acute pancreatitis and the increased risk of congenital malformations (when administered during pregnancy) with the use of carbimazole and thiamazole.[105]European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals. Jan 2019 [internet publication]. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-26-29-november-2018-prac-meeting_en.pdf [106]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: risk of acute pancreatitis. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-risk-of-acute-pancreatitis [107]Medicines and Healthcare products Regulatory Agency. Drug safety alert: carbimazole: increased risk of congenital malformations; strengthened advice on contraception. Feb 2019 [internet publication]. https://www.gov.uk/drug-safety-update/carbimazole-increased-risk-of-congenital-malformations-strengthened-advice-on-contraception Propylthiouracil is associated with hepatic toxicity. Thiamazole should be used initially in all patients except during the first trimester of pregnancy due to its increased association with birth defects.[48]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018 Jul 25;7(4):167-86. https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml http://www.ncbi.nlm.nih.gov/pubmed/30283735?tool=bestpractice.com [108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Adverse effects of antithyroid drugs include the following.
Skin rash: develops in 7% to 12% of patients; if mild, may improve with antihistamine treatment.[101]Abraham P, Avenel A, Park CM, et al. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol. 2005 Oct;153(4):489-98. http://www.ncbi.nlm.nih.gov/pubmed/16189168?tool=bestpractice.com [109]Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012 Aug;77(2):310-5. http://www.ncbi.nlm.nih.gov/pubmed/22332800?tool=bestpractice.com
Agranulocytosis: a rare adverse effect seen in 0.1% to 0.5% of patients.[110]Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013 Dec;98(12):4776-83. http://www.ncbi.nlm.nih.gov/pubmed/24057289?tool=bestpractice.com All patients taking antithyroid drugs should be educated and warned about the early symptoms of agranulocytosis, and advised to stop taking the medicine and seek urgent medical attention if these symptoms develop.
If antithyroid drugs are discontinued because of adverse effects during pregnancy, second-trimester thyroidectomy is the only other option for symptomatic patients.[108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Primary options
propylthiouracil: adults: 50-300 mg/day orally given in 3 divided doses initially, consult specialist for further guidance
OR
carbimazole: adults: consult specialist for guidance on dose
OR
thiamazole: adults: consult specialist for guidance on dose
symptomatic therapy
Additional treatment recommended for SOME patients in selected patient group
Offer a beta-blocker such as propranolol for early symptomatic relief until specific therapy normalises peripheral thyroid hormone levels.
Beta-blockers ameliorate adrenergic symptoms such as tachycardia, tremor, and anxiety. Taper dose when specific therapy becomes effective. Beta-blockers are not indicated if there is a history of asthma, bradycardia, or heart block.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com
Propranolol has been associated with neonatal hypoglycaemia, apnoea, and bradycardia as well as intrauterine growth restriction, so its use should be minimised or fetal growth should be closely monitored if it is used long-term.[148]Redmond GP. Propranolol and fetal growth retardation. Semin Perinatol. 1982 Apr;6(2):142-7. http://www.ncbi.nlm.nih.gov/pubmed/7100933?tool=bestpractice.com
Calcium-channel blockers are discouraged as their effects on the fetus are not known.
Primary options
propranolol: adults: 80-160 mg orally (extended-release) once daily
OR
labetalol: adults: 100-200 mg orally twice daily
thyroid surgery
Surgery during pregnancy is rarely necessary, as low-dose antithyroid drug treatment usually suffices. If antithyroid drugs are discontinued because of adverse effects during pregnancy, second-trimester thyroidectomy is the only other option for symptomatic patients.[108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
preoperative medical preparation
Treatment recommended for ALL patients in selected patient group
Beta-blockers are initiated in preparation for second-trimester thyroidectomy in patients with adverse effects to antithyroid drugs.
Beta-blockers are stopped after surgery.
Primary options
propranolol: adults: 80-160 mg orally (extended-release) once daily
OR
labetalol: adults: 100-200 mg orally twice daily
postoperative thyroid replacement
Treatment recommended for ALL patients in selected patient group
Hypothyroidism must be avoided during pregnancy to avert adverse effects on the fetus.
Treatment with levothyroxine is as indicated for hypothyroidism. Replacement thyroxine therapy should be monitored with serum thyroid-stimulating hormone (TSH) at 4-week intervals until stable during pregnancy. Measurement of free T4 is a much less sensitive parameter of the thyroid metabolic state. However, when pituitary TSH production is suppressed by a prolonged period of thyrotoxic state due to high TSH receptor antibodies, it may take some months for pituitary function to recover; during that interval, measurement of serum TSH may be misleading, and free T4 may give a better indication of thyroid status. Dose requirements may reduce after delivery, and will again need to be titrated. Once stable, TSH should be measured at least annually.
Primary options
levothyroxine: adults: consult specialist for guidance on dose
children
antithyroid drugs (prolonged)
Antithyroid drugs, radioactive iodine, and surgery are options for treating Graves’ hyperthyroidism in children.[48]Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J. 2018 Jul 25;7(4):167-86. https://etj.bioscientifica.com/view/journals/etj/7/4/ETJ490384.xml http://www.ncbi.nlm.nih.gov/pubmed/30283735?tool=bestpractice.com [138]Mooij CF, Cheetham TD, Verburg FA, et al. 2022 European Thyroid Association guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022 Jan 1;11(1):e210073. https://etj.bioscientifica.com/view/journals/etj/11/1/ETJ-21-0073.xml http://www.ncbi.nlm.nih.gov/pubmed/34981748?tool=bestpractice.com
Discuss the possible benefits and risks of these treatment options and the likelihood of a good response with patients (and their parents and carers, as appropriate) and take their preferences and values into account in addition to their clinical characteristics.
In children, antithyroid drug treatment is considered first choice, but results in a relapse rate of about 70% after 1-2 years.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com [139]Glaser NS, Styne DM; Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics. 2008 Mar;121(3):e481-8. http://www.ncbi.nlm.nih.gov/pubmed/18267979?tool=bestpractice.com [140]Lane LC, Cheetham T. Graves' disease: developments in first-line antithyroid drugs in the young. Expert Rev Endocrinol Metab. 2020 Mar;15(2):59-69. http://www.ncbi.nlm.nih.gov/pubmed/32133893?tool=bestpractice.com However, prolonged treatment (8-10 years) may be associated with up to a 50% remission rate.[141]Leger J, Gelwane G, Kaguelidou F, et al; French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab. 2012 Jan;97(1):110-9. http://www.ncbi.nlm.nih.gov/pubmed/22031519?tool=bestpractice.com In these cases, low-dose drug treatment until maturity is appropriate, then surgery (only by experienced paediatric surgeons) or radioiodine should be considered.[142]Kaguelidou F, Carel JC, Léger J. Graves' disease in childhood: advances in management with antithyroid drug therapy. Horm Res. 2009;71(6):310-7. http://www.ncbi.nlm.nih.gov/pubmed/19506387?tool=bestpractice.com
Propylthiouracil has an unacceptable risk of life-threatening hepatic injury in children, and should only be used rarely for brief periods (e.g., while waiting for thyroidectomy).[108]US Food and Drug Administration. Drug safety communication: new boxed warning on severe liver injury with propylthiouracil. Apr 2010 [internet publication]. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-boxed-warning-severe-liver-injury-propylthiouracil#ds
Primary options
carbimazole: children: consult specialist for guidance on dose
OR
thiamazole: children: consult specialist for guidance on dose
Secondary options
propylthiouracil: children: consult specialist for guidance on dose
symptomatic therapy
Additional treatment recommended for SOME patients in selected patient group
Offer a beta-blocker such as propranolol for early symptomatic relief until specific therapy normalises peripheral thyroid hormone levels.
Beta-blockers ameliorate adrenergic symptoms such as tachycardia, tremor, and anxiety. Taper dose when specific therapy becomes effective. Beta-blockers are not indicated if there is a history of asthma, bradycardia, or heart block.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com
Calcium-channel blockers are an alternative if beta-blockers are not tolerated or are contraindicated.
Primary options
propranolol: children: consult specialist for guidance on dose
Secondary options
atenolol: children: consult specialist for guidance on dose
Tertiary options
diltiazem: children: consult specialist for guidance on dose
OR
verapamil: children: consult specialist for guidance on dose
thyroid surgery
Surgery is preferred for younger children (e.g., <5 years) and those with Graves’ orbitopathy or a thyroid nodule.[49]Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-421. http://online.liebertpub.com/doi/full/10.1089/thy.2016.0229 http://www.ncbi.nlm.nih.gov/pubmed/27521067?tool=bestpractice.com [138]Mooij CF, Cheetham TD, Verburg FA, et al. 2022 European Thyroid Association guideline for the management of pediatric Graves' disease. Eur Thyroid J. 2022 Jan 1;11(1):e210073. https://etj.bioscientifica.com/view/journals/etj/11/1/ETJ-21-0073.xml http://www.ncbi.nlm.nih.gov/pubmed/34981748?tool=bestpractice.com [143]Quintanilla-Dieck L, Khalatbari HK, Dinauer CA, et al. Management of pediatric Graves disease: a review. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1110-8. http://www.ncbi.nlm.nih.gov/pubmed/34647991?tool=bestpractice.com
Surgery is, however, usually a second-line option for children, and can be considered: if a child experiences severe adverse effects with antithyroid therapy; when prolonged therapy has not resulted in remission; or when relapse occurs after a course of antithyroid treatment.
Surgical complications are more common in children than in adults.[143]Quintanilla-Dieck L, Khalatbari HK, Dinauer CA, et al. Management of pediatric Graves disease: a review. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1110-8. http://www.ncbi.nlm.nih.gov/pubmed/34647991?tool=bestpractice.com [144]Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008 Aug;93(8):3058-65. https://academic.oup.com/jcem/article/93/8/3058/2598650 http://www.ncbi.nlm.nih.gov/pubmed/18522977?tool=bestpractice.com Minimally invasive thyroid surgery may be considered in some patients.[133]Miccoli P, Fregoli L, Rossi L, et al. Minimally invasive video-assisted thyroidectomy (MIVAT). Gland Surg. 2020 Jan;9(suppl 1):S1-S5. https://www.doi.org/10.21037/gs.2019.12.05 http://www.ncbi.nlm.nih.gov/pubmed/32055492?tool=bestpractice.com [145]De Napoli L, Spinelli C, Ambrosini CE, et al. Minimally invasive video-assisted thyroidectomy versus conventional thyroidectomy in pediatric patients. Eur J Pediatr Surg. 2014 Oct;24(5):398-402. https://www.doi.org/10.1055/s-0033-1351391 http://www.ncbi.nlm.nih.gov/pubmed/24000127?tool=bestpractice.com Total or near-total thyroidectomy is preferred over bilateral subtotal thyroidectomy as it prevents recurrent hyperthyroidism; levothyroxine therapy is started immediately postoperatively if the patient is euthyroid at the time of surgery.[128]Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg. 2012 Apr;99(4):515-22. http://www.ncbi.nlm.nih.gov/pubmed/22287122?tool=bestpractice.com [146]Thompson GB. Surgical management in Graves' disease. Panminerva Med. 2002 Dec;44(4):287-93.[147]Barakate MS, Agarwal G, Reeve TS, et al. Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg. 2002 May;72(5):321-4. http://www.ncbi.nlm.nih.gov/pubmed/12028087?tool=bestpractice.com
Radioactive iodine may be an alternative option for children aged over 10 years. It should only be considered for those aged 5-10 years if surgery is not an option. Radioactive iodine should be avoided in children aged under 5 years.
preoperative medical preparation
Treatment recommended for ALL patients in selected patient group
If surgery is considered appropriate, patients are prepared with antithyroid drugs until euthyroidism is achieved. Some clinics treat patients 7-10 days prior to surgery with pharmacological doses of iodine (e.g., Lugol solution or SSKI) to reduce vascularity of the thyroid gland.
Beta-blockers are used for symptomatic therapy; calcium-channel blockers are an alternative if beta-blockers are not tolerated or are contraindicated.[2]Smith TJ, Hegedüs L. Graves' disease. N Engl J Med. 2016 Oct 20;375(16):1552-65. http://www.ncbi.nlm.nih.gov/pubmed/27797318?tool=bestpractice.com [143]Quintanilla-Dieck L, Khalatbari HK, Dinauer CA, et al. Management of pediatric Graves disease: a review. JAMA Otolaryngol Head Neck Surg. 2021 Dec 1;147(12):1110-8. http://www.ncbi.nlm.nih.gov/pubmed/34647991?tool=bestpractice.com
Primary options
propranolol: children: consult specialist for guidance on dose
or
atenolol: children: consult specialist for guidance on dose
-- AND / OR --
carbimazole: children: consult specialist for guidance on dose
or
thiamazole: children: consult specialist for guidance on dose
or
propylthiouracil: children: consult specialist for guidance on dose
-- AND / OR --
iodine/potassium iodide: (Lugol solution: iodine 5%/potassium iodine 10%) children: consult specialist for guidance on dose
or
potassium iodide: children: consult specialist for guidance on dose
postoperative thyroid replacement
Treatment recommended for ALL patients in selected patient group
Total or near-total thyroidectomy is preferred over bilateral subtotal thyroidectomy as it prevents recurrent hyperthyroidism; levothyroxine therapy is started immediately postoperatively if the patient is euthyroid at the time of surgery.[128]Barczynski M, Konturek A, Hubalewska-Dydejczyk A, et al. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br J Surg. 2012 Apr;99(4):515-22. http://www.ncbi.nlm.nih.gov/pubmed/22287122?tool=bestpractice.com [146]Thompson GB. Surgical management in Graves' disease. Panminerva Med. 2002 Dec;44(4):287-93.[147]Barakate MS, Agarwal G, Reeve TS, et al. Total thyroidectomy is now the preferred option for the surgical management of Graves' disease. ANZ J Surg. 2002 May;72(5):321-4. http://www.ncbi.nlm.nih.gov/pubmed/12028087?tool=bestpractice.com
Primary options
levothyroxine: children: consult specialist for guidance on dose
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer